Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2007
11/27/2007US7300946 For use in controlling insects; controlling tobacco budworm
11/27/2007US7300945 For therapy of of certain central nervous system (CNS) diseases, anxiety, depression, a sleep disorder, schizophrenia, or attention deficit-hyperactivity disorder
11/27/2007US7300944 Alzheimer's disease, bipolar disorder, diabetes, dementia, stroke, schizophrenia, depression, hair loss, cancer
11/27/2007US7300943 Pyrazolo[3,4-b]pyridin-6-ones which are inhibitors of cyclin-dependent protein kinases and glycogen synthase kinase; diabetes, dementia, Alzheimer's disease, stroke, schizophrenia, alopecia, and cancer; antiasthmatics, angiogenesis inhibitors; antiproliferative, neuroprotective and neuroleptic agents
11/27/2007US7300942 For therapy of a fungal infection
11/27/2007US7300941 Non-imidazole compounds
11/27/2007US7300940 Such as 4-[2-(3,4,5,6-Tetrahydropyrimidin-2-ylamino)ethyloxy]benzoyl-2-(S)-[N-(3-amino-neopenta-1-carbamyl)]-aminoethylsulfonylamino- beta -alanine Hydrochloride; for therapy and prophylaxis of disease conditions that are associated with the biological activity of integrin receptors
11/27/2007US7300939 For therapy of neuropathic pain
11/27/2007US7300938 Polymorphs of imatinib mesylate
11/27/2007US7300937 Derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication
11/27/2007US7300936 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors
11/27/2007US7300935 Gonadotropin-releasing hormone antagonistic activity, therapy of prostatic cancer, endometriosis, precocious puberty; N-(4-(1-(2,6-difluorobenzyl)-5-(((2-ethoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea
11/27/2007US7300934 carbocyclic carboxy nitriles such as 4-chloro-N-[2-({[(1S)-1-cyano-2-thien-3-ylethyl]amino}carbonyl)cyclohexyl]benzamide, used as cathepsin inhibitors; antimetastatic and antitumor agents; prophylaxis of cardiovascular and bone disorders
11/27/2007US7300933 Diazabicyclic biaryl derivatives
11/27/2007US7300932 For treatment or prevention of metabolic and cell proliferative diseases; modifying lipid metabolism
11/27/2007US7300931 Compositions for treating cell proliferation disorders
11/27/2007US7300930 Therapeutic acridone and acridine compounds
11/27/2007US7300929 Mediators of hedgehog signaling pathways, compositions and uses related thereto
11/27/2007US7300928 Benzimidazolidinone derivatives as muscarinic agents
11/27/2007US7300927 Method for treating or preventing Alzheimer's disease
11/27/2007US7300926 Bioavailability; prevention therapy of osteoporosis ; menopause therapy; side effect reduction
11/27/2007US7300925 treating psoriasis with e.g. 19-nor-2beta-ethyl-1alpha,25-dihydroxyvitamin D3
11/27/2007US7300924 Conjugate of rifampicin linked to one or more phosphonate groups; allows accumulation or retention inside cells; improved anti-infective activity and pharmacokinetic properties, including oral bioavailability, greater potency and half-life in vivo
11/27/2007US7300923 Partial and full agonists of A1 adenosine receptors
11/27/2007US7300922 Enhancing or inhibiting the biological activity of nucleic acid ligands by administrating a modulator, to change the binding of the nucleic acid ligand for its target or degrading or cleaving
11/27/2007US7300921 with antibiotic activity; made by cultivation of Amycolatopsis orientalis
11/27/2007US7300920 N-terminal sequences of human growth hormone, human placental lactogen, human growth hormone variant hGH-V, and prolactin; used in inhibiting angiogenesis and in the diagnosis of diseases of human pregnancy involving abnormal placental
11/27/2007US7300917 Remedy for chronic disease
11/27/2007US7300678 Using white almond paste; prevent wrinkling of skins
11/27/2007US7300674 Sterile low bicarbonate dialysis concentrate solutions
11/27/2007US7300673 exposing substrates to metal ions, then to basic environments to form thin films comprising antimicrobially active oxidized silver; medical equipment
11/27/2007US7300670 Oral suspension formulation
11/27/2007US7300669 Fatty alcohol, skin conditioner, propylene glycol, mineral oil or white soft paraffin and water; fluticasone propionate and oil in water emulsion includig excipients; antiinflammatory agents
11/27/2007US7300666 Mixture for transdermal delivery of low and high molecular weight compounds
11/27/2007US7300664 Vaginally administrable progesterone-containing tablets and method for preparing same
11/27/2007US7300663 Adhesion and sealing of tissue with compositions containing polyfunctional crosslinking agents and protein polymers
11/27/2007US7300662 Local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography, lower systemic toxicity
11/27/2007US7300657 Recombinant viral-based malaria vaccines
11/27/2007US7300654 Method of treating corneal transplant rejection in high risk keratoplasty patients
11/27/2007US7300653 Method of treating corneal transplant rejection
11/27/2007US7300649 For treating an undesirable skin condition of a mammal selected from the group consisting of adverse signs of aging of the skin, a dull complexion, skin or hair pigmentation disorders, and skin dryness, or a pathological skin condition of a mammal selected from the group consisting of acne vulgaris
11/27/2007US7300646 Skin lightening agents, compositions and methods
11/27/2007US7300645 Oral composition comprising isomalt and remineralizing enhancing agent
11/27/2007CA2525874C Pharmaceutical compositions of varenicline
11/27/2007CA2432196C Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors
11/27/2007CA2400377C Method for treating ocular pain
11/27/2007CA2379695C Compounds for modulating the rage receptor
11/27/2007CA2358998C Substituted bicyclic derivatives useful as anticancer agents
11/27/2007CA2344313C Agents for periodontal disease
11/27/2007CA2338896C Fast dissolving ibuprofen containing compositions having analgesic activity
11/27/2007CA2336412C Medicament for treatment of diabetes
11/27/2007CA2335328C A substituted triazolo-pyridazine derivative, pharmaceutical compositions made therefrom
11/27/2007CA2329622C Remineralizing oral compositions comprising palatinit
11/27/2007CA2306883C Fast-dissolving pharmaceutical composition comprising as-3201
11/27/2007CA2299710C Aryloxyaniline derivatives
11/27/2007CA2292600C Compositions and methods for inhibiting photoaging of skin
11/27/2007CA2290557C Use of 4-substituted tetrahydropyridines for making medicines acting on tgf-.beta.1
11/27/2007CA2285332C Nutritional supplement for facilitating skeletal muscle adaptation to strenuous exercise and counteracting defatigation in asthenic individuals
11/27/2007CA2271683C Coated particles, methods of making and using
11/27/2007CA2267932C Compositions for postgastrectomic mineral supply
11/27/2007CA2264097C Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
11/27/2007CA2253613C Therapeutic treatment for vegf related occular diseases
11/27/2007CA2186892C Methods for treating pulmonary vasoconstriction and asthma
11/25/2007CA2590355A1 Polymeric stent having modified molecular structures in selected regions of the flexible connectors
11/25/2007CA2590321A1 Polymeric stent having modified molecular structures in the flexible connectors and in the radial struts and the radial arcs of the hoops
11/25/2007CA2590318A1 Polymeric stent having modified molecular structures in both the hoops and selected segments of the flexible connectors
11/25/2007CA2590313A1 Polmeric stent having modified molecular structures in the flexible connections
11/25/2007CA2590310A1 Polymeric stent having modified molecular structures in the flexible connectors and the radial arcs of the hoops
11/25/2007CA2590305A1 Polymeric stent having modified molecular structures
11/25/2007CA2590264A1 Polymeric stent having modified molecular structures in the flexible connectors and the radial struts of the hoops
11/24/2007CA2590122A1 Tartrate salt of isofagomine and methods of use
11/23/2007CA2589819A1 Method for treatment of neurodegenerative disorders
11/22/2007WO2007134342A2 A teaching aid
11/22/2007WO2007134309A2 Systems, methods, and apparatuses for advertisement generation, selection and distribution system registration
11/22/2007WO2007134292A2 Treprostinil administration using a metered dose inhaler
11/22/2007WO2007134282A2 Stroller with spring-assisted fold mechanism
11/22/2007WO2007134271A2 Method and apparatus for reducing injury from acute myocardial infarction
11/22/2007WO2007134256A2 Apparatus and method for ablation-related dermatological treatment of selected targets
11/22/2007WO2007134203A2 Anticancer treatments with a combination of docetaxel and ecteinascidin
11/22/2007WO2007134132A2 Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
11/22/2007WO2007134107A2 Cold menthol receptor-1 antagonists
11/22/2007WO2007134077A2 5 ht receptor mediated neurogenesis
11/22/2007WO2007134055A1 Antibacterial extracellular polysaccharide solvating system
11/22/2007WO2007134034A1 Polymorph forms of (2s) - (4e) -n-methyl-5- (3-isopropoxypyridin) yl] -4-penten-2-amine for the treatment of central nervous system disorders
11/22/2007WO2007133987A2 System and method for identifying non-event profiles
11/22/2007WO2007133981A1 Novel composition and method effective in inhibiting the atherogenic process
11/22/2007WO2007133948A2 Apparatus for reducing nox emissions in furnaces through the concentration of solid fuel as compared to air
11/22/2007WO2007133944A2 Topical administration of acyclovir
11/22/2007WO2007133940A2 Fuel cell assembly using multiple fuel cell stacks and control method therefor
11/22/2007WO2007133935A2 Method and materials to control doping profile in integrated circuit substrate material
11/22/2007WO2007133923A2 Interactive interface for electronic devices
11/22/2007WO2007133812A2 Improved carriers for delivery of nucleic acid agents to cells and tissues
11/22/2007WO2007133810A2 Methods for providing stand-in services for transaction card customization
11/22/2007WO2007133809A2 Separable sheath and method of use
11/22/2007WO2007133808A2 Nano-particles for cosmetic applications
11/22/2007WO2007133805A2 Aerogel-based enclosure systems
11/22/2007WO2007133803A2 Treatment of mycobacterial infections
11/22/2007WO2007133802A2 Pharmaceutical formulations of pimavanserin
11/22/2007WO2007133801A2 Magnetic microparticles comprising organic substances
11/22/2007WO2007133800A2 Toll-like receptor (tlr) stimulation for ocular angiogenesis and macular degeneration
1 ... 3487 3488 3489 3490 3491 3492 3493 3494 3495 3496 3497 3498 3499 3500 3501 3502 3503 3504 3505 3506 3507 ... 7860